Inhibitation of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil

World Journal of Gastroenterology

Volumn 12, Issue 42, 2006, Pages 6766-6770

  Liu, Jian ^a,b   Xu, Wen Fang ^a   Cui, Shu Xiang ^c   Zhou, Yong ^d   Yuan, Yun Xia ^a   Chen, Ming Hui ^a   Wang, Ruo Han ^c   Gai, Ruo Yan ^e   Makuuchi, Masatoshi ^e   Tang, Wei ^a,e   Qu, Xian Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Traditional Chinese Medicine University   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d Center for Drug Evaluation and Certification of Shandong   (China)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Gastric carcinoma cells; Growth inhibition; N3 o toluyl fluorouracil; Pro drug

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FLUOROURACIL DERIVATIVE; MICROSOME ENZYME; N3 O TOLUYLFLUOROURACIL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ATOFLUDING; DRUG DERIVATIVE; FLUOROURACIL; N3 O TOLUYL FLUOROURACIL; N3-O-TOLUYL-FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; STATISTICAL ANALYSIS; STOMACH CARCINOMA; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; EVALUATION; LIVER; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LIVER; MALE; MICE; MICE, NUDE; RATS; RATS, SPRAGUE-DAWLEY; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33751382328     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i42.6766     Document Type: Article

References (23)

1. Martinez J, Martin C, Chacon M, Korbenfeld E, Bella S, Senna. S, Richardet E, Coppola F, Bas C, Hidalgo J, Escobar E, Reale M, Smilovich AM, Wasserman E. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. Am J Clin Oncol 2006; 29: 45-51
2. Sassi G, Striano B, Merlo UA. A reporting system for the assessment of chemotherapy toxicity. J Oncol Pharm Pract 2005; 11: 63-67
3. Wu SL, Sun ZJ, Yu L, Meng KW, Qin XL, Pan CE. Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol 2004; 10: 3048-3052
4. Schmidt Laugesen C, Steffansen B, Scherfig E, la Cour M. Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs. Acta Ophthalmol Scand 2005; 83: 184-190
5. Krishnaiah YS, Satyanarayana V, Dinesh Kumar B, Karthikeyan RS, Bhaskar P. In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. Eur J Pharm Sci 2003; 19: 355-362
6. Berglund A, Carlsson G, Gustavsson B, Frodin JE, Ragnhammar P, Glimelius B. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma. Anticancer Res 2003; 23: 1789-1794
7. El-Khoueiry AB, Lenz HJ. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest 2006; 24: 50-55
8. Xu W, Zhang Z, Castaner J. Atofluding. Drugs Fut 2001; 26: 935-938
9. Kametani T, Kigasawa K, Hiiragi M, Wakisaka. K, Haga S, Nagamatsu Y, Sugi H, Fukawa K, Irino O, Yamamoto T, Nishimura N, Taguchi A, Okada T, Nakayama M. Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives. J Med Chem 1980; 23: 1324-1329
10. Qu XJ, Yang JL, Russell PJ, Goldstein D. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 2004; 172: 733-738
11. Rastogi S, Das M, Khanna SK. A novel approach to study the activity and stoichiometry simultaneously for microsomal pentoxyresorufin-O-dealkylase reaction. FEBS Lett 2002; 512: 121-124
12. Das M, Rastogi S, Khanna SK. Mechanism to study 1:1 stoichiometry of NADPH and alkoxyphenoxazones metabolism spectrophotometrically in subcellular biological preparations. Biochim Biophys Acta 2004; 1675: 1-11
13. Yang JL, Qu XJ, Russell PJ, Goldstein D. Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. Gut 2004; 53: 123-129
14. Cui SX, Qu XJ, Xie YY, Zhou L, Nakata M, Makuuchi M, Tang W. Curcumin inhibits telomerase activity in human cancer cell lines. Int J Mol Med 2006; 18: 227-231
15. Li Q Feng FY, Han J, Sui GJ, Zhu YG, Zhang Y, Zhang ZH, Li L, Wang PH, Zhou MZ, Zhang YC. Phase III clinical study of a new anticancer drug atofluding. Aizheng 2002; 21: 1350-1353
16. Park JY, Kim KA. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms; in human liver microsomes. Eur J Clin Pharmacol 2003; 59: 407-409
17. Peet CF, Enos T, Nave R, Zech K, Hall M. Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet 2005; 30: 275-286
18. Simeonova M, Velichkova R, Ivanova G, Enchev V, Abrahams I. Study on the role of 5-fluorouracil in the polymerization of butylcyanoacrylate during the formation of nanoparticles. J Drug Target 2004; 12: 49-56
19. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005; 4: 855-863
20. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nonomura M, Nakao M, Miki T. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 2003; 9: 1453-1460
21. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587.194-205
22. Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine. World J Gastroenterol 2004; 10: 172-176
23. Yamamoto S, Kubota K. Level of 5-fluorodeoxyuridine 5′-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1. A preliminary study. J Exp Clin Cancer Res 2005; 24: 457-462